Stem Cell-Derived 'Living Drug' takes aim at tough autoimmune conditions

NCT ID NCT07301164

Not yet recruiting Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safety and find the right dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCT301 (anti-CD19 CAR-iT cells derived from chemically induced pluripotent stem cells)
What this could lead to: If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong: This is a very early, small trial (10 people) focused on safety, not yet on effectiveness. The therapy involves strong chemotherapy beforehand and carries risks like severe immune reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome granulomatosis with polyangiitis idiopathic inflammatory myopathy Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS ANTIPHOSPHOLIPID SYNDROME INFLAMMATORY MYOSITIS SJOGREN SYNDROME SYSTEM; LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS (SSC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.